IMpassion031: Atezolizumab Fails To Significantly Improve Early-Stage TNBC Survival
From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival